Genetic testing in ovarian cancer

Genetic Testing for Breast and Ovarian Cancer

Genetic testing for breast and ovarian cancer has been publicly available since the mid-1990 discovery of two breast/ovarian cancer susceptibility genes named BRCA1 and BRCA2. Although many professionals say that genetic testing may be the best available preventative medicine breakthrough, controversy abounds over whether the medical benefits of BRCA1/2 mutation testing outweigh the psychologic...

Genetic Testing for Hereditary Breast and Ovarian Cancer

Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered s...

New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study

BACKGROUND Over recent years genetic testing for germline mutations in BRCA1/BRCA2 has become more readily available because of technological advances and reducing costs. OBJECTIVE To explore the feasibility and acceptability of offering genetic testing to all women recently diagnosed with epithelial ovarian cancer (EOC). METHODS Between 1 July 2013 and 30 June 2015 women newly diagnosed wi...

Genetic testing in cancer therapeutics.

A major challenge to physicians administering drugs with a low therapeutic index, such as chemotherapeutic agents, is the variability in drug disposition and clearance. This variability accounts for the wide interpatient response to conventional doses of antineoplastic agents. Currently, most dosing regimens are based on body weight or surface area, with the decision for dose modifications typi...